Autopsy report · NCT00348712
Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes
Cause of deathNo reason given
“See termination reason in detailed description”
Life of this trial
- Registered 4 months before it started.
- Ran for about 1 year 4 months before it stopped.
- 301 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Conditions
- Diabetes; Diabetes Mellitus, Type 2
- Interventions
- rosiglitazone; inhaled human insulin; metformin
- Participants
- 301
- Sites
- 74
- Countries
- Austria, Finland, France, Germany, Ireland, Netherlands, Spain, Switzerland, United Kingdom
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.